Crenezumab PK and amyloid-beta binding
A TMDD PK/PD model coupling intravenous crenezumab disposition to free and antibody-bound amyloid-beta 1-40 and 1-42 turnover.
- Therapeutic
- Crenezumab, MABT5102A, RG7412
- Target
- Amyloid beta / APP, beta-amyloid, Abeta(1-40), Abeta(1-42)
- Disease
- Alzheimer disease
Biological model
A TMDD PK/PD model coupling intravenous crenezumab disposition to free and antibody-bound amyloid-beta 1-40 and 1-42 turnover.
Model details
A TMDD PK/PD model coupling intravenous crenezumab disposition to free and antibody-bound amyloid-beta 1-40 and 1-42 turnover.
Modeled states
- AUC crenezumab nM daynM*day
Modeled dynamic state for auc crenezumab nm day.
- AUC free abeta40 pM daypM*day
Modeled dynamic state for auc free abeta40 pm day.
- AUC free abeta42 pM daypM*day
Modeled dynamic state for auc free abeta42 pm day.
- A central nmolnmol
Modeled dynamic state for a central nmol.
- A depot nmolnmol
Modeled dynamic state for a depot nmol.
- A peripheral nmolnmol
Modeled dynamic state for a peripheral nmol.
- T abeta40 pMpM
Modeled dynamic state for t abeta40 pm.
- T abeta42 pMpM
Modeled dynamic state for t abeta42 pm.
- elapsed dayday
Modeled dynamic state for elapsed day.
Key readouts
- Crenezumab concentrationunknown
Model-derived readout for crenezumab concentration.
- Free amyloid-beta 1-40unknown
Model-derived readout for free amyloid-beta 1-40.
- Free amyloid-beta 1-42unknown
Model-derived readout for free amyloid-beta 1-42.
- Crenezumab–amyloid-beta 1-40 complexunknown
Model-derived readout for crenezumab–amyloid-beta 1-40 complex.
- Crenezumab–amyloid-beta 1-42 complexunknown
Model-derived readout for crenezumab–amyloid-beta 1-42 complex.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
style 15 mg/kg every 4 weeks IV
How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time? Explore this intervention regimen through Crenezumab concentration, Free amyloid-beta 1-40, Free amyloid-beta 1-42, Crenezumab–amyloid-beta 1-40 complex, Crenezumab–amyloid-beta 1-42 complex. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does crenezumab dose change free and bound amyloid-beta 1-40 and 1-42 over time?
CLel L day
Model parameter controlling clel l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s diseaseAlzheimer's Research & Therapy
